Fen Phen Update: Pondimin and Redux Claims Are Still Being Filed and Paid

Fen Phen lawyer Cynthia K. Garrett reports that worsened injury claims may still be filed for those who took the diet drugs Pondimin or Redux, registered with the AHP Settlement Trust by May 3, 2003, established the required baseline injury during the Screening Period that ended in 2003, did not participate in the Seventh Amendment Supplemental Fund, and currently qualify for a Matrix Compensation Level and dollar value above any previous award received.

Garrett explained, “Whether you can still file a claim depends upon the nature and extent of your injury, when your worst injury was first diagnosed, and what has previously been filed in your case. The criteria you must meet to file a claim today is discussed at length on my website, CKGLawFim.com. I’ve provided you with a quick summary below.”

Who Can Still File A Claim:

Qualifying injuries must have been diagnosed prior to your 80th birthday.
If you opted-out of the 7th Amendment and have not yet received Matrix Compensation benefits, and you can show that any matrix level condition was present before December 31, 2015, you may file an Original Claim for Matrix Compensation.

If you have already received Matrix Compensation and did not participate in the 7th Amendment Supplemental Fund you may file a Supplemental Claim if you have been diagnosed with a medical condition that qualifies for a Matrix Compensation Level and dollar value above any previous Matrix Compensation award you have received.

If you participated in the 7th Amendment Supplemental Fund the deadline for filing a claim has expired.
The deadline for filing a Matrix Compensation claim with the AHP Settlement Trust is four years from the date you were first diagnosed as having the last occurring condition or event upon which the claim for Matrix Compensation Benefits is based.

Qualifying Injuries:
According to Garrett, some of the medical conditions that qualify

Judge won’t let Pfizer rid itself of inherited fen-phen scourge

Pfizer just can’t get rid of the specter of fen-phen. Fifteen years after the diet drug was removed from the market over serious health concerns, litigation lingers and the drugmaker’s move to kill that off fell short yesterday.

Pfizer has reserved $21 billion for fen-phen litigation over the years but hoped to have remaining suits dismissed. But a judge in Philadelphia, where most of the suits are consolidated, wasn’t buying it. He said plaintiffs can use studies from experts that indicate that fen-phen can instigate primary pulmonary hypertension, even more than a decade after consumers stopped taking the appetite suppressant. Pfizer tells Bloomberg that it is weighing its legal options.

Pfizer bought the problem when it acquired the drug’s developer Wyeth in 2009, 12 years after fen-phen was banned in the U.S. More than 6 million prescriptions had been written when it was on the market, Bloomberg says, and at one time there were more than 175,000 claims that the combo diet drug had caused health problems, sometimes leading to early deaths.

Wyeth originally set up a $1.3 billion fund in 2004 to cover the potential losses, but over the years that escalated as litigation and potential liability grew. By the time Pfizer entered the picture, the fund was at $21.1 billion.

Of course, lingering litigation is common to many drugmakers. Pfizer in June, for example, reported in a financial filing that it had paid out nearly $900 million on about 6,000 injury cases related to the hormone replacement Prempro and had 

Lasting Damage From Fen-Phen Drug

Study Shows Lingering Heart Valve Problems in Former Users of Banned Obesity Drugs Fenfluramine and Dexfenfluramine

Two banned obesity drugs may have lingering effects on the heart, according to a new study.

The study shows that heart valve problems linked to the banned obesity drugs fenfluramine and/or dexfenfluramine typically last years after stopping those drugs.

The FDA ordered fenfluramine and dexfenfluramine off the market in September 1997 after those drugs were linked to heart valve problems. Fenfluramine was one of the ingredients in “fen-phen,” and dexfenfluramine is closely related to fenfluramine. The “phen” in fen-phen refers to a drug called phentermine, which wasn’t banned.

The new study, published online today in BMC Medicine, shows what happened to the hearts of 5,743 former users of fenfluramine and/or dexfenfluramine.

Heart Valve Problems

The patients were seen by doctors including Charles Dahl, MD, of the Central Utah Clinic in Provo, Utah, between July 1997 and February 2004.

During that time, each patient got an echocardiogram and 1,020 patients got two or more echocardiograms 30 months apart, on average.

Dahl’s team searched the echocardiograms for signs of blood leaking back through heart valves (regurgitation), and they noted which patients got surgery to correct heart valve problems.

Fen-Phen Lawyers Charged With Defrauding Clients

Two of the owners of the Preakness champion Curlin were indicted yesterday by a federal grand jury on a charge that they conspired to defraud their clients in a $200 million lawsuit settlement with the maker of the diet drug fen-phen.

The grand jury in Covington, Ky., indicted the lawyers Shirley A. Cunningham Jr., 52, and William J. Gallion, 56, on one count each of conspiracy to commit wire fraud.

If convicted, each could receive a maximum of 20 years in prison and a $250,000 fine. The federal sentencing guidelines are no longer mandatory, so it is unlikely they will receive the maximum penalty if they are found guilty.

The grand jury also handed up one forfeiture count each, which would require the defendants, if

Cases of Fen-Phen and SSRI-Related Lung Disorder Rise

In the fall of 1997, American Home Products Corporation, which became Wyeth in 2002, withdrew the drugs Pondimin (fenfluramine), and Redux (dexfenfluramine), which were prescribed together with phentermine for weight loss, in a combination called “fen-phen,” for short.

Fen-phen causes the life-threatening lung disorder known as primary pulmonary hypertension, or PPH. According to the Pulmonary Hypertension Association, PPH is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery rises above normal levels and can become life threatening.

As the blood is pumped through the arteries in the lungs, it receives oxygen; this oxygenated blood returns to the heart where it is then transported to the rest of the body through the aorta and other arteries. Changes to the

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in a plaintiffs’ legal claim. Words such as ‘loans,’ ‘lender,’ 'interest', ‘borrower,’ and phrases such as 'lawsuit loans' and 'settlement loans' are used for relatability, search, and marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408